NovaDel Pharma reports $1.31m net loss in Q3
NovaDel Pharma’s loss from operations was $1.52m, compared to $1.28m for the comparable period in 2009. For the nine months ended 30 September 2010, NovaDel has posted a
Vertex Pharmaceuticals and Genomics have agreed a four-year extension to their drug discovery partnership in a deal with a potential value exceeding $220m.
Collis previously was executive vice president of AmerisourceBergen and president of AmerisourceBergen Drug (ABDC), the company’s largest subsidiary. Prior to that he was executive vice president of AmerisourceBergen
Echo Therapeutics is developing needle-free Symphony tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system and Prelude SkinPrep System for transdermal drug delivery. Echo said that